Evidence map›Paper›PMID 37072432›Full record

ReviewCell death discovery2023

The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases.

Ruyuan He, Bohao Liu, Boxin Geng, Ning Li, Qing Geng

Abstract readReview
In one paragraph

Review in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Phytic acid (InsPNature communications · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Regulation ofInternational journal of molecular sciences · 2025
    Review
  16. Article
  17. Histone deacetylases and their inhibitors in kidney diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  18. Article
  19. NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruyuan He *Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Bohao Liu *Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Boxin Geng *School of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, China.
Ning LiDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China. md.lining@whu.edu.cn.ORCID http://orcid.org/0000-0003-3175-8343
Qing GengDepartment of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China. gengqingwhu@whu.edu.cn.ORCID http://orcid.org/0000-0003-0870-9893

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81770095National Natural Science Foundation of China (National Science Foundation of China) 8210082163Natural Science Foundation of Hubei Province (Hubei Provincial Natural Science Foundation) 2020CFA027
6 · The paper itself

Abstract

HDAC3 is a specific and crucial member of the HDAC family. It is required for embryonic growth, development, and physiological function. The regulation of oxidative stress is an important factor in intracellular homeostasis and signal transduction. Currently, HDAC3 has been found to regulate several oxidative stress-related processes and molecules dependent on its deacetylase and non-enzymatic activities. In this review, we comprehensively summarize the knowledge of the relationship of HDAC3 with mitochondria function and metabolism, ROS-produced enzymes, antioxidant enzymes, and oxidative stress-associated transcription factors. We also discuss the role of HDAC3 and its inhibitors in some chronic cardiovascular, kidney, and neurodegenerative diseases. Due to the simultaneous existence of enzyme activity and non-enzyme activity, HDAC3 and the development of its selective inhibitors still need further exploration in the future.

Identifiers

PMID37072432
PMCPMC10113195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.